Nippon India Nifty Pharma ETF
EquitySector - HealthcareVery High Risk
Direct
NAV (25-Jul-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹639 Cr
Expense Ratio
0.21%
ISIN
INF204KC1089
Minimum SIP
-
Exit Load
-
Inception Date
06 Jul 2021
About this fund
As of 25-Jul-24, it has a Net Asset Value (NAV) of ₹21.49, Assets Under Management (AUM) of 638.88 Crores, and an expense ratio of 0.21%.
- Nippon India Nifty Pharma ETF has given a CAGR return of 14.00% since inception.
- The fund's asset allocation comprises around 99.92% in equities, 0.00% in debts, and 0.08% in cash & cash equivalents.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+47.38%
+45.90% (Cat Avg.)
3 Years
+13.73%
+14.66% (Cat Avg.)
Since Inception
+14.00%
— (Cat Avg.)
Portfolio Summaryas of 30th June 2024
| Equity | ₹638.36 Cr | 99.92% |
| Others | ₹0.53 Cr | 0.08% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹153.92 Cr | 24.09% |
| Dr Reddy's Laboratories Ltd | Equity | ₹73.09 Cr | 11.44% |
| Cipla Ltd | Equity | ₹72.86 Cr | 11.40% |
| Divi's Laboratories Ltd | Equity | ₹54.9 Cr | 8.59% |
| Lupin Ltd | Equity | ₹36.72 Cr | 5.75% |
| Aurobindo Pharma Ltd | Equity | ₹31.84 Cr | 4.98% |
| Zydus Lifesciences Ltd | Equity | ₹25.32 Cr | 3.96% |
| Torrent Pharmaceuticals Ltd | Equity | ₹23.91 Cr | 3.74% |
| Alkem Laboratories Ltd | Equity | ₹23.5 Cr | 3.68% |
| Mankind Pharma Ltd | Equity | ₹18.38 Cr | 2.88% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹17.25 Cr | 2.70% |
| Laurus Labs Ltd | Equity | ₹15.66 Cr | 2.45% |
| Biocon Ltd | Equity | ₹14.62 Cr | 2.29% |
| Ipca Laboratories Ltd | Equity | ₹14.24 Cr | 2.23% |
| Abbott India Ltd | Equity | ₹13.76 Cr | 2.15% |
| Gland Pharma Ltd | Equity | ₹11.84 Cr | 1.85% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹11.74 Cr | 1.84% |
| Natco Pharma Ltd | Equity | ₹9.94 Cr | 1.56% |
| Granules India Ltd | Equity | ₹6.27 Cr | 0.98% |
| Sanofi India Ltd | Equity | ₹5.48 Cr | 0.86% |
| Sanofi Consumer He | Equity | ₹3.13 Cr | 0.49% |
| Triparty Repo | Cash - Repurchase Agreement | ₹0.73 Cr | 0.11% |
| Net Current Assets | Cash | ₹-0.21 Cr | 0.03% |
| Cash Margin - Ccil | Cash - Collateral | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
62.15%
Mid Cap Stocks
29.59%
Small Cap Stocks
7.68%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹635.22 Cr | 99.43% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Fund Managers
Himanshu Mange
Since December 2023
Additional Scheme Detailsas of 30th June 2024
ISIN | INF204KC1089 | Expense Ratio | 0.21% | Exit Load | - | Fund Size | ₹639 Cr | Age | 06 Jul 2021 | Lumpsum Minimum | - | Fund Status | Open Ended Investment Company | Benchmark | Nifty Pharma TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Withdrawal within 1 year
Flat 15% tax on realised gains (STCG - short term capital gains)
Withdrawal after 1 year
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
About the AMC
Total AUM
₹4,96,196 Cr
Address
4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013
Other Funds by Nippon India Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Nippon India Nifty Pharma ETF?
What are the returns of Nippon India Nifty Pharma ETF?
What is the portfolio composition of Nippon India Nifty Pharma ETF?
Who manages the Nippon India Nifty Pharma ETF?
- Himanshu Mange
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.